- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 368 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- August 2025
- 150 Pages
Global
From €3459EUR$3,950USD£3,003GBP
- Report
- December 2025
- 150 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- April 2025
- 144 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- January 2026
- 187 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 185 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- January 2026
- 182 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- December 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- February 2026
- 503 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 201 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 171 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP

The Autologous Stem Cell market is a subset of the larger Stem Cell market. Autologous stem cells are those derived from the patient's own body, and are used to treat a variety of conditions, including degenerative diseases, autoimmune diseases, and tissue damage. Autologous stem cells are typically harvested from the patient's bone marrow, adipose tissue, or peripheral blood. The cells are then processed and expanded in the laboratory before being re-injected into the patient.
The Autologous Stem Cell market is growing rapidly, driven by advances in stem cell technology and the increasing availability of treatments. The market is expected to continue to expand as more treatments become available and the technology continues to improve.
Some companies in the Autologous Stem Cell market include Osiris Therapeutics, Inc., Athersys, Inc., Mesoblast Limited, and Pluristem Therapeutics, Inc. Show Less Read more